The
very first affected person has been enrolled straight into the Phase 1 clinical
trial sponsored by Viral Genetics' (OTC Pink: VRAL) and based on a donation
from Scott and White Foundation. The trial would study Metabolic Disruption
Technology (MDT) compounds in conjunction with an existing cancer session as a
treatment for drug-resistant ovarian cancer.
A
total of up to 24 affected individuals will receive combination remedy for hydroxychloroquine
and sorafenib under primary investigator, Tyler Curiel, M.D., MPH, a scientific
oncologist associated with The Cancer Therapy and Research Center (CTRC) of The
University of Texas Health Science Center at San Antonio. This test is the first
financed by Viral Genetics based on the licensed study of Dr. M. Karen
Newell-Rogers, the Company's Chief Scientist, and represents a milestone within
the transition of this very Company from preclinical- to actually
clinical-stage. Affected person selection is likewise expected to initiate at
Scott and White Hospital as soon as internal examination procedures there will
be finalized.
"Affected
individual enrollment marks the proper launch of a clinical trial therefore we
are pretty happy in order to get underway after much homework and difficult
work by our group members, and Dr. Curiel's group," said Haig Keledjian, president
of Viral Genetics. "I will emphasize that many of us would not have
proceeded with this decision of one MDT compound if we and our advisors were
not sure that it held real promise for affected individuals, but one should
also appreciate the severity of the illnesses we happen to be attempting to
deal with in this study. We recommend optimistic, but cautious and outstanding
predictions."
No comments:
Post a Comment